However, a retrospective study showed that the response of PE of lung cancer patients with EGFR mutation and MPE to EGFR-TKIs (including gefitinib, alfatinib and oxitinib) was worse than that of solid malignant tumors [84]. This evidence concerns the gene EGFR and lung carcinoma.